convEyXO

What convEyXO does

convEyXO is a Belgian biotechnology company founded in 2019 and headquartered in Charleroi, developing RNA-enhanced exosome therapeutics built on its iMSC 2.0 platform of engineered mesenchymal-stem-cell-derived exosomes. The company's underlying technology combines a proprietary immortalized Wharton's jelly MSC line (WJ-iMSC hTert273, cited at 100x cell-doubling capacity) with mechanoporation-based miRNA loading (cited at 10x absorption efficiency), supported by the EXO-Harvest bioreactor manufacturing system (wholly owned subsidiary) and the XomeXBio bioinformatics joint venture with SomesTech for miRNA profiling. Management claims a roughly 40x production cost advantage and the ability to derive approximately 1 billion doses from a single donor.

Its lead clinical-stage assets are EXOSTEO01 for osteoarthritis and DERMEXO01 for dermatological conditions, with additional research directed at inflammatory bowel disease via a 2025 SATT Paris-Saclay partnership and broader exploration of chronic inflammation, gut, kidney, and neurological indications. First-in-human studies are targeted for early 2027. The company is pre-revenue, has 11–50 employees, and has raised approximately $12.2M cumulatively between 2020 and 2024.

The business model is a development-stage biotech monetization path: future revenue is expected to come from licensing deals, pharma partnerships, and eventual commercialization of exosome therapeutics, with manufacturing potentially supported by the EXO-Harvest bioreactor platform. Currently the company has no paying customers; counterparty relationships are research collaborations (SATT Paris-Saclay, Saudi Biotechnology Accelerator) and the SomesTech joint venture. Geographic expansion is underway into China via a December 2025 Suzhou agreement and into Saudi Arabia via the 2025 accelerator program, while organizational buildout is evidenced by CFO and Operations Manager appointments in mid-to-late 2025.

Name

convEyXO

Legal name

Conveyxo

Website

https://conveyxo.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

convEyXO is a Belgian biotech developing RNA-enhanced exosome therapeutics via its iMSC 2.0 platform and mechanoporation loading technology, targeting osteoarthritis (EXOSTEO01), dermatology (DERMEXO01), and inflammatory bowel disease, with first-in-human studies planned for early 2027.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

akta.pro secondary industries

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

Keywords

• Exosome therapeutics
• Regenerative medicine
• RNA-enhanced exosomes
• Cell-free therapies
• Biopharmaceutical platform

Headquarters

HQ city

Gosselies

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. RNA-Enhanced Exosome Therapeutics: Pre-revenue biotech company developing proprietary RNA-enhanced exosome therapeutics for degenerative and inflammatory diseases. Future revenue expected from pharmaceutical licensing and product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

convEyXO develops RNA-enhanced exosome therapeutics designed to reduce inflammation, restore cellular balance, and address the biological roots of degenerative and inflammatory diseases. Its integrated proprietary platform spans engineered iMSC 2.0 exosomes, the Exo-Harvest perfusion bioreactor manufacturing system, XomeXBio bioinformatics and miRNA profiling, patented mechanoporation cargo loading, and the WJ-iMSC hTert273 immortalized cell line. The company is advancing two lead therapeutic programs—EXOSTEO01 (osteoarthritis) and DERMEXO01 (dermatological conditions)—toward first-in-human studies planned for early 2027.

Product overview

convEyXO offers a unified technology platform for RNA-enhanced exosome therapeutics focused on osteoarthritis and dermatological conditions. The platform integrates multiple proprietary technologies: iMSC 2.0 (engineered mesenchymal stem cell-derived exosomes), Exo-Harvest (bioreactor-based manufacturing), XomeXBio (bioinformatics analysis), miRNA Enhancement (cargo loading), and the Engineering Platform (mechanoporation). The company develops therapeutic programs including EXOSTEO01 and DERMEXO01, with strategic partnerships extending to chronic inflammatory, gut, kidney, and neuro-related diseases.

Differentiator

Problem solved

Functional benefit

Brands

• EXO-Harvest: Proprietary system for isolating, purifying, and scaling exosomes with clinical-grade precision; also refers to multi-scale bioreactor platform for adherent cells and extracellular vesicles production.
• XomeXBio
• EXOSTEO01
• DERMEXO01

Quantifiable outcome

• 40x cost reduction vs competitors through proprietary bioreactor technology
• +3 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• SATT Paris-SaclaycoreStrategic or Co-development Partner · 1 October 2025Collaboration to load miRNA cargo into convEyXO's exosomes and evaluate therapeutic impact against intestinal inflammation (IBD). This partnership extends the platform into inflammatory bowel disease applications.
• IPRATECHcoreTechnology or Integration · 15 July 2024Partnership for launch of cutting-edge multi-scale bioreactor platform for adherent cells and extracellular vesicles (EVs) production. The Exo-Harvest affiliate of convEyXO partnered with IPRATECH to develop scalable manufacturing solutions.
• SomesTechcoreStrategic or Co-development Partner · 26 May 2023Joint venture XomeXBio created to develop the full potential of targeted exosomes as drug delivery system for precision medicine. The joint venture leverages both companies' expertise in exosome technology.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Evox Therapeutics: UK-based leading engineered exosome therapeutics company developing exosome-based treatments for rare diseases and CNS indications. Closest direct competitor to convEyXO given similar engineered MSC-derived EV approach and pre-clinical/early clinical stage.
• Mesoblast: Australia/US-based allogeneic cell therapy company with remestemcel-L approved for pediatric SR-aGvHD and in development for inflammatory/orthopedic indications. Direct therapeutic competitor to convEyXO's EXOSTEO01 osteoarthritis program.
• Aruna Bio: US-based exosome therapeutics company developing neural stem cell-derived extracellular vesicles for CNS and inflammatory conditions. Comparable in using stem cell-derived EVs as therapeutic modality with similar mechanism of action.
• Anjarium Biosciences: Swiss-based engineered exosome therapeutics company developing a targeted exosome platform for gene therapy, oncology, and inflammatory diseases. Directly comparable hybrid exosome-plus-payload approach to convEyXO.
• Capricor Therapeutics: US biotech with both cell therapy (CAP-1002) and exosome-based (CAP-2003) programs targeting inflammatory and rare disease indications. Comparable therapeutic positioning in exosome-based anti-inflammatory modality.
• Ilias Biologics: Korean exosome-based protein delivery company developing engineered exosomes (including exosome engineering technology) for inflammatory and rare diseases. Directly comparable approach of loading therapeutic cargo into exosomes.
• Carmine Therapeutics: Exosome-based gene therapy platform (now part of Takeda) developing engineered EVs for rare diseases. Comparable technology approach of engineering exosomes to carry therapeutic cargo, including nucleic acids.

Regional players

• ExoCoBio: Korean exosome therapeutics and cosmeceuticals company with stem cell-derived EV products. Relevant as regional peer in dermatology (DERMEXO01 competitor) and exosome manufacturing, though primarily serving Asian markets.

Emerging players

• Pluristem Therapeutics: Israeli cell therapy company developing placenta-derived cell therapies for inflammatory conditions and orthopedic indications. Comparable allogeneic cell-derived therapeutic approach targeting similar regenerative indications.

Broad incumbents

• Arcturus Therapeutics: Clinical-stage RNA therapeutics company with proprietary LNP delivery platform and multiple RNA programs in clinical development. Broad incumbent in RNA delivery space that convEyXO also targets with its exosome-based RNA delivery platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about convEyXO